Role of somatostatin receptors in normal and tumoral pituitary corticotropic cells

Neuroendocrinology

Volumn 92, Issue SUPPL. 1, 2010, Pages 11-16

  Hofland, Leo J ^a   Lamberts, Steven W J ^a   Feelders, Richard A ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Adenoma; Adrenocorticotropic hormone; Corticotrope; Cortisol; Glucocorticoids; Pituitary; Somatostatin receptor

Indexed keywords

ANGIOPEPTIN; CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR; GLUCOCORTICOID; GROWTH HORMONE; HYDROCORTISONE; LUTEINIZING HORMONE; OCTREOTIDE; PASIREOTIDE; PROLACTIN; SOMATOSTATIN 14; SOMATOSTATIN RECEPTOR; THYROTROPIN;

CONFERENCE PAPER; CORTICOTROPIN BLOOD LEVEL; CORTICOTROPIN RELEASE; CORTICOTROPIN TEST; CUSHING DISEASE; HORMONE RECEPTOR INTERACTION; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYDROCORTISONE RELEASE; HYPOPHYSIS ADENOMA; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RECEPTOR AFFINITY;

ADRENOCORTICOTROPIC HORMONE; CORTICOTROPHS; HUMANS; PITUITARY GLAND; PITUITARY NEOPLASMS; RECEPTORS, SOMATOSTATIN;

EID: 77956538048     PISSN: 00283835     EISSN: None     Source Type: Journal    
DOI: 10.1159/000314296     Document Type: Conference Paper

References (39)

1. Brazeau P, Vale W, Burgus R, Ling N, Butcher M, Rivier J, Guillemin R: Hypothalamic polypeptide that inhibits the secretion of im-munoreactive pituitary growth hormone. Science 1973; 179:77-79.
2. Patel YC: Somatostatin and its receptor family. Front Neuroendocrinol 1999; 20:157-198.
3. Lamberts SW, Van Der Lely AJ, De Herder WW, Hofland LJ: Octreotide. N Engl J Med 1996; 334: 246-254.
4. Weckbecker G, Lewis I, Albert R, Schmid HA, Hoyer D, Bruns C: Opportunities in somatostatin research: biological, chemical and therapeutic aspects. Nat Rev Drug Dis-cov 2003; 2: 999-1017.
5. Lamberts SW, Zuyderwijk J, Den Holder F, Van Koetsveld P, Hofland L: Studies on the conditions determining the inhibitory effect of somatostatin on adrenocorticotropin, prolactin and thyrotropin release by cultured rat pituitary cells. Neuroendocrinolo-gy 1989; 50:44-50.
6. Shimon I, Taylor JE, Dong JZ, Bitonte RA, Kim S, Morgan B, Coy DH, Culler MD, Melmed S: Somatostatin receptor subtype specificity in human fetal pituitary cultures. Differential role of sstr2 and sstr5 for growth hormone, thyroid-stimulating hormone, and prolactin regulation. J Clin Invest 1997; 99: 789-798.
7. O'Carroll AM, Krempels K: Widespread distribution of somatostatin receptor messenger ribonucleic acids in rat pituitary. Endo-crinolog y 1995; 136: 5224-5227.
8. Day R, Dong W, Panetta R, Kraicer J, Greenwood MT, Patel YC: Expression of mRNA for somatostatin receptor (sstr) types 2 and 5 in individual rat pituitary cells. A double labeling in situ hybridization analysis. Endocri-nolog y 1995; 136: 5232-5235.
9. Mezey E, Hunyady B, Mitra S, Hayes E, Liu Q, Schaeffer J, Schonbrunn A: Cell specific expression of the sst2a and sst5 somatostatin receptors in the rat anterior pituitary. Endo-crinolog y 1998; 139: 414-419.
10. Brown MR, Rivier C, Vale W: Central nervous system regulation of adrenocorticotro-pin secretion: role of somatostatins. Endocrinology 1984; 114:1546-1549. (Pubitemid 14140301)
11. Kraicer J, Gajewski TC, Moor BC: Release of pro-opiomelanocortin-derived peptides from the pars intermedia and pa rs dista lis of the rat pituitary: effect of corticotrophin-re-leasing factor and somatostatin. Neuroendo-crinology 1985; 41:363-373.
12. Voight KH, Fehm HL, Lang RE, Walter R: The effect of somatostatin and of prolyl-leucyl-glycinamide (mif) on ACTH release in dispersed pituitary cells. Life Sci 1977; 21: 739-745.
13. Volpi R, Chiodera P, Capretti L, Caiazza A, Caffarri G, Magotti MG, Boni S, Coiro V: Inhibition by somatostatin of the growth hormone, but not corticotropin response to an-giotensin II in normal men. Horm Res 1996; 45: 269-272.
14. Stafford PJ, Kopelman PG, Davidson K, McLoughlin L, White A, Rees LH, Besser GM, Coy DH, Grossman A: The pituitary-adrenal response to crf-41 is unaltered by intravenous somatostatin in normal subjects. Clin Endocrinol (Oxf) 1989; 30: 661-666.
15. Broglio F, Arvat E, Benso A, Gottero C, Pro-da m F, Grot tol i S, Papot ti M, Muccioli G, Van Der Lely AJ, Deghenghi R, Ghigo E: Endocrine activities of cortistatin-14 and its interaction with GHRH and ghrelin in humans. J Clin Endocrinol Metab 2002; 87: 3783-3790.
16. Fehm HL, Voigt KH, Lang R, Beinert KE, Raptis S, Pfeiffer EF: Somatostatin: a potent inhibitor of ACTH-hypersecretion in adrenal insufficiency. Klin Wochenschr 1976; 54: 173-175.
17. Silva AP, Schoeffter P, Weckbecker G, Bruns C, Schmid HA: Regulation of CRH-induced secretion of ACTH and corticosterone by SOM230 in rats. Eur J Endocrinol 2005; 153:R7-R10.
18. Richardson UI, Schonbrunn A: Inhibition of adrenocorticotropin secretion by somatosta-tin in pituitary cells in culture. Endocrinology 1981; 108:281-290.
19. Batista DL, Zhang X, Gejman R, Ansell PJ, Zhou Y, Johnson SA, Swearingen B, Hedley-Whyte ET, Stratakis CA, Klibanski A: The effects of SOM230 on cell proliferation and adrenocorticotropin secretion in human corticotroph pituitary adenomas. J Clin En-docrinol Metab 2006; 91:4482-4488.
20. Tateno T, K ato M, Ta n i Y, O ya ma K, Ya mad a S, Hirata Y: Differential expression of soma-tostatin and dopamine receptor subtype genes in adrenocorticotropin (ACTH)-se-creting pituitary tumors and silent cortico-troph adenomas. Endocr J 2009;56:579-584.
21. Saveanu A, Jaquet P: Somatostatin-dopa-mine ligands in the treatment of pituitary adenomas. Rev Endocr Metab Disord 2009; 10:83-90.
22. Hofland LJ, Van Der Hoek J, Feelders R, Van Aken MO, Van Koetsveld PM, Waaijers M, Sprij-Mooij D, Bruns C, Weckbecker G, De Herder WW, Beckers A, Lamberts SW: The multi-ligand somatostatin analogue SOM230 inhibits acth secretion by cultured human corticotroph adenomas via soma-tostatin receptor type 5. Eur J Endocrinol 2005; 152: 645-654.
23. De Bruin C, Pereira AM, Feelders RA, Rom-ijn JA, Roelfsema F, Sprij-Mooij DM, Van Aken MO, Van Der Lelij AJ, De Herder WW, Lamberts SW, Hofland LJ: Coexpression of dopamine and somatostatin receptor subtypes in corticotroph adenomas. J Clin En-docrinol Metab 2009; 94: 111 8-11 2 4.
24. Hassaneen W, Cahill DP, Fuller GN, Levine NB: Immunohistochemical detection of so-matostatin receptor subtype 5 (SSTR-5) in Cushing adenoma. J Neurooncol 2010;98: 151-152.
25. Van Der Hoek J, Waaijers M, Van Koetsveld PM, Sprij-Mooij D, Feelders RA, Schmid HA, Schoeffter P, Hoyer D, Cervia D, Taylor JE, Culler MD, Lamberts SW, Hofland LJ: Distinct functional properties of native so-matostatin receptor subtype 5 compared with subtype 2 in the regulation of ACTH release by corticotroph tumor cells. Am J Physiol Endocrinol Metab 2005; 289:E278-E287.
26. Ben-Shlomo A, Schmid H, Wawrowsky K, Pichurin O, Hubina E, Chesnokova V, Liu NA, Culler M, Melmed S: Differential li-gand-mediated pituitary somatostatin receptor subtype signaling: implications for corticotroph tumor therapy. J Clin Endocri-nol Metab 20 09; 94: 4342-4350.
27. Lamberts SW, Uitterlinden P, Klijn JM: The effect of the long-acting somatostatin analogue sms 201-995 on ACTH secretion in Nelson's syndrome and Cushing's disease. Acta Endocrinol (Copenh) 1989; 120:760-766.
28. Ambrosi B, Bochicchio D, Ferrario R, Colombo P, Faglia G: Screening tests for Cush-ing's syndrome. Clin Endocrinol (Oxf) 1990; 33: 809-811.
29. Tyrrell JB, Lorenzi M, Gerich JE, Forsham PH: Inhibition by somatostatin of ACTH secretion in Nelson's syndrome. J Clin Endo-crinol Metab 1975; 40:1125-1127.
30. Schonbrunn A: Glucocorticoids down-regulate somatostatin receptors on pituitary cells in culture. Endocrinology 1982; 110:1147-115 4.
31. Boscaro M, Ludlam WH, Atkinson B, Glus-man JE, Petersenn S, Reincke M, Snyder P, Tabarin A, Biller BM, Findling J, Melmed S, Darby CH, Hu K, Wang Y, Freda PU, Grossman AB, Frohman LA, Bertherat J: Treatment of pituitary-dependent cushing's disease with the multireceptor ligand so-matostatin analog pasireotide (som230): a multicenter, phase II trial. J Clin Endocrinol Metab 20 09; 94: 11 5-1 2 2.
32. Pivonello R, Ferone D, De Herder WW, Kros JM, De Caro ML, Arvigo M, Annunziato L, Lombardi G, Colao A, Hofland LJ, Lamberts SW: Dopamine receptor expression and function in corticotroph pituitary tumors. J Clin Endocrinol Metab 2004; 89:2452-2462. (Pubitemid 38619889)
33. Pivonello R, De Martino MC, Cappabianca P, De Leo M, Faggiano A, Lombardi G, Ho-fland LJ, Lamberts SW, Colao A: The medical treatment of Cushing's disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery. J Clin Endocrinol Metab 2009; 94: 223-230.
34. De Bruin C, Feelders RA, Waaijers AM, Van Koetsveld PM, Sprij-Mooij DM, Lamberts SW, Hofland LJ: Differential regulation of human dopamine D2 and somatostatin receptor subtype expression by glucocorti-coids in vitro. J Mol Endocrinol 2009; 42:47-56.
35. Feelders RA, De Bruin C, Pereira AM, Rom-ijn JA, Netea-Maier RT, Hermus AR, Zelis-sen PM, De Jong FH, Van Der Lely AJ, De Herder WW, Hofland LJ, Lamberts SWJ: Stepwise medical treatment of Cushing's disease with pasireotide mono-or combination therapy with cabergoline and low-dose keto-conazole. N Engl J Med 2010;362:1846-1848.
36. Saveanu A, Gunz G, Guillen S, Dufour H, Culler MD, Jaquet P: Somatostatin and do-pamine-somatostatin multiple ligands directed towards somatostatin and dopamine receptors in pituitary adenomas. Neuroen-docrinology 2006; 83: 258-263.
37. Bruns C, Lewis I, Briner U, Meno-Tetang G, Weckbecker G: SOM230: a novel somatosta-tin peptidomimetic with broad somatotro-pin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol 2002; 146:707-716.
38. Jaque t P, Gu n z G, S ave a nu A, D u fou r H, Taylor J, Dong J, Kim S, Moreau JP, Enjalbert A, Culler MD: Efficacy of chimeric molecules directed towards multiple somatostatin and dopa m i ne re c eptors on in h ibit ion of GH a nd prolactin secretion from GH-secreting pituitary adenomas classified as partially responsive to somatostat in a na log t herapy. Eur J Endocrinol 20 05; 153: 135-141.
39. Ren SG, Taylor J, Dong J, Yu R, Culler MD, Melmed S: Functional association of soma-tostatin receptor subtypes 2 and 5 in inhibiting human growth hormone secretion. J Clin Endocrinol Metab 2003; 88:4239-4245.